Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 9/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.41 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13929793 | 0.87 | PLAU (0.45) | PLAUPGK1FGFR3FGFR1FGFR2 | |
| SCHEMBL10046375 | 0.86 | PLAU (0.42) | PLAUFGFR3FGFR1FGFR2KDR | |
| SCHEMBL10015201 | 0.84 | FGFR3 (0.41) | FGFR3KDRMAPTCSF1RAXL | |
| SCHEMBL15433735 | 0.82 | BRD4 (0.43) | PLAUFGFR3FGFR1FGFR2KDR | |
| SCHEMBL288379 | 0.80 | MEN1 (0.50) | MAPT | |
| SCHEMBL289476 | 0.78 | TDO2 (0.44) | MAPT | |
| SCHEMBL15433942 | 0.76 | CYP19A1 (0.39) | MAPT | |
| SCHEMBL289177 | 0.76 | SMN1; SMN2 (0.43) | MAPT | |
| SCHEMBL288188 | 0.76 | RAC1 (0.49) | KDRMAPT | |
| SCHEMBL289055 | 0.76 | PDGFRB (0.39) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427434-B1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INT (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-2427434-B1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INT (DE) | 2017-05-31 | — | — | EP | disclosed |
| US-8633320-B2 | Process for preparing bromo-substituted quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-8633320-B2 | Process for preparing bromo-substituted quinolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-21 | — | — | US | disclosed |
| US-20120165534-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| US-20120165534-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
| EP-2427434-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | Boehringer Ingelheim International GmbH (DE) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129451-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129451-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165534-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | HCCS, CYP3A7, ABL1 | PLAU 4480/4885PGK1 2595/4885FGFR3 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.